Depression - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Depression - Pipeline Review, H2 2018’, provides an overview of the Depression pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Depression, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Depression and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Depression

- The report reviews pipeline therapeutics for Depression by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Depression therapeutics and enlists all their major and minor projects

- The report assesses Depression therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Depression

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Depression

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Depression pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Acadia Pharmaceuticals Inc

Ache Laboratorios Farmaceuticos SA

Adamed Sp z oo

Addex Therapeutics Ltd

Aequus Pharmaceuticals Inc

Albany Molecular Research Inc

Alkermes Plc

Allergan Plc ...

Acadia Pharmaceuticals Inc

Ache Laboratorios Farmaceuticos SA

Adamed Sp z oo

Addex Therapeutics Ltd

Aequus Pharmaceuticals Inc

Albany Molecular Research Inc

Alkermes Plc

Allergan Plc

Amorsa Therapeutics Inc

Anavex Life Sciences Corp

Avanir Pharmaceuticals Inc

Axsome Therapeutics Inc

Azevan Pharmaceuticals Inc

BioCrea GmbH

Bionomics Ltd

BioXcel Therapeutics Inc

Blackthorn Therapeutics Inc

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

Calico LLC

Celgene Corp

Cellix Bio Pvt Ltd

Celon Pharma SA

Cerecor Inc

Clera Inc

Delpor Inc

DURECT Corp

Eisai Co Ltd

Eli Lilly and Co

Fabre-Kramer Pharmaceuticals Inc

FPRT Bio Inc

GlaxoSmithKline Plc

GliaCure Inc

H. Lundbeck AS

Heptares Therapeutics Ltd

Impel NeuroPharma Inc

Intas Pharmaceuticals Ltd

IntelGenx Corp

Intra-Cellular Therapies Inc

Jiangsu Nhwa Pharmaceutical Corp Ltd

Johnson & Johnson

Karuna Pharmaceuticals Inc

KemPharm Inc

Kissei Pharmaceutical Co Ltd

Lead Discovery Center GmbH

Les Laboratoires Servier SAS

Lixte Biotechnology Holdings Inc

Luye Pharma Group Ltd

Mapi Pharma Ltd

Mapreg SAS

MedinCell SA

Medlab Clinical Ltd

Meta-IQ ApS

Mitsubishi Tanabe Pharma Corp

Navitor Pharmaceuticals Inc

Neuralstem Inc

Neurocrine Biosciences Inc

NeuroNascent Inc

Nippon Chemiphar Co Ltd

Novartis AG

Omeros Corp

Otsuka Holdings Co Ltd

Pfizer Inc

Pherin Pharmaceuticals Inc

Protagenic Therapeutics Inc

Relmada Therapeutics Inc

Reviva Pharmaceuticals Inc

Richter Gedeon Nyrt

Sage Therapeutics Inc

Shenox Pharmaceuticals LLC

SK Biopharmaceuticals Co Ltd

Sound Pharmaceuticals Inc

Sumitomo Chemical Co Ltd

Sumitomo Dainippon Pharma Co Ltd

Sunovion Pharmaceuticals Inc

Supernus Pharmaceuticals Inc

Syntropharma Ltd

Taisho Pharmaceutical Holdings Co Ltd

Takeda Pharmaceutical Co Ltd

Trevena Inc

VistaGen Therapeutics Inc

Zysis Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 7

Depression – Overview 8

Depression – Therapeutics Development 9

Depression – Therapeutics Assessment 32

Depression – Companies Involved in Therapeutics ...

Table of Contents

Table of Contents 2

Introduction 7

Depression – Overview 8

Depression – Therapeutics Development 9

Depression – Therapeutics Assessment 32

Depression – Companies Involved in Therapeutics Development 47

Depression – Drug Profiles 86

Depression – Dormant Projects 449

Depression – Discontinued Products 466

Depression – Product Development Milestones 471

Appendix 484

List of Tables

List of Tables

Number of Products under Development for Depression, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under ...

List of Tables

Number of Products under Development for Depression, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Products under Development by Universities/Institutes, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Depression – Pipeline by Acadia Pharmaceuticals Inc, H2 2018

Depression – Pipeline by Ache Laboratorios Farmaceuticos SA, H2 2018

Depression – Pipeline by Adamed Sp z oo, H2 2018

Depression – Pipeline by Addex Therapeutics Ltd, H2 2018

Depression – Pipeline by Aequus Pharmaceuticals Inc, H2 2018

Depression – Pipeline by Albany Molecular Research Inc, H2 2018

Depression – Pipeline by Alkermes Plc, H2 2018

Depression – Pipeline by Allergan Plc, H2 2018

Depression – Pipeline by Amorsa Therapeutics Inc, H2 2018

Depression – Pipeline by Anavex Life Sciences Corp, H2 2018

Depression – Pipeline by Avanir Pharmaceuticals Inc, H2 2018

Depression – Pipeline by Axsome Therapeutics Inc, H2 2018

Depression – Pipeline by Azevan Pharmaceuticals Inc, H2 2018

Depression – Pipeline by BioCrea GmbH, H2 2018

Depression – Pipeline by Bionomics Ltd, H2 2018

Depression – Pipeline by BioXcel Therapeutics Inc, H2 2018

Depression – Pipeline by Blackthorn Therapeutics Inc, H2 2018

Depression – Pipeline by Boehringer Ingelheim GmbH, H2 2018

Depression – Pipeline by Bristol-Myers Squibb Co, H2 2018

Depression – Pipeline by Calico LLC, H2 2018

Depression – Pipeline by Celgene Corp, H2 2018

Depression – Pipeline by Cellix Bio Pvt Ltd, H2 2018

Depression – Pipeline by Celon Pharma SA, H2 2018

Depression – Pipeline by Cerecor Inc, H2 2018

Depression – Pipeline by Clera Inc, H2 2018

Depression – Pipeline by Delpor Inc, H2 2018

Depression – Pipeline by DURECT Corp, H2 2018

Depression – Pipeline by Eisai Co Ltd, H2 2018

Depression – Pipeline by Eli Lilly and Co, H2 2018

Depression – Pipeline by Fabre-Kramer Pharmaceuticals Inc, H2 2018

Depression – Pipeline by FPRT Bio Inc, H2 2018

Depression – Pipeline by GlaxoSmithKline Plc, H2 2018

Depression – Pipeline by GliaCure Inc, H2 2018

Depression – Pipeline by H. Lundbeck AS, H2 2018

Depression – Pipeline by Heptares Therapeutics Ltd, H2 2018

Depression – Pipeline by Impel NeuroPharma Inc, H2 2018

Depression – Pipeline by Intas Pharmaceuticals Ltd, H2 2018

Depression – Pipeline by IntelGenx Corp, H2 2018

Depression – Pipeline by Intra-Cellular Therapies Inc, H2 2018

Depression – Pipeline by Jiangsu Nhwa Pharmaceutical Corp Ltd, H2 2018

Depression – Pipeline by Johnson & Johnson, H2 2018

Depression – Pipeline by Karuna Pharmaceuticals Inc, H2 2018

Depression – Pipeline by KemPharm Inc, H2 2018

Depression – Pipeline by Kissei Pharmaceutical Co Ltd, H2 2018

Depression – Pipeline by Lead Discovery Center GmbH, H2 2018

Depression – Pipeline by Les Laboratoires Servier SAS, H2 2018

Depression – Pipeline by Lixte Biotechnology Holdings Inc, H2 2018

Depression – Pipeline by Luye Pharma Group Ltd, H2 2018

List of Figures

List of Figures

Number of Products under Development for Depression, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under ...

List of Figures

Number of Products under Development for Depression, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports